Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Silence Therapeutics Plc ADR (SLN)

Silence Therapeutics Plc ADR (SLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Silence Therapeutics Plc ADR 12 HAMMERSMITH GROVE OFFICE 205 LONDON X0 W6 7AP GBR

www.silence-therapeutics.com Employees: 116 P: 44-20-3457-6900

Sector:

Medical

Description:

Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein and SLN500 for the treatment of complement-mediated diseases which are in clinical stage. Silence Therapeutics plc is based in London, the United Kingdom.

Key Statistics

Overview:

Market Capitalization, $K 211,608
Enterprise Value, $K 90,278
Shares Outstanding, K 47,234
Float, K 45,297
% Float 95.90%
Short Interest, K 1,328
Short Float 2.81%
Days to Cover 3.75
Short Volume Ratio 0.59
% of Insider Shareholders 4.10%
% of Institutional Shareholders 98.73%

Financials:

Annual Sales, $ 43,260 K
Annual Net Income, $ -45,310 K
Last Quarter Sales, $ 160 K
Last Quarter Net Income, $ -20,960 K
EBIT, $ -84,220 K
EBITDA, $ -83,630 K

Growth:

1-Year Return 3.85%
3-Year Return -64.78%
5-Year Return -81.59%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.45 on 11/06/25
Next Earnings Date 02/26/26 [--]
Earnings Per Share ttm -1.32
EPS Growth vs. Prev Qtr 16.67%
EPS Growth vs. Prev Year 40.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

SLN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -61.76%
Return-on-Assets % -36.62%
Profit Margin % -104.74%
Debt/Equity 0.00
Price/Sales 8.19
Price/Cash Flow N/A
Price/Book 1.01
Book Value/Share 0.00
Interest Coverage -0.65
60-Month Beta 1.34
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar